[go: up one dir, main page]

WO2008124000A3 - Thiazole derivatives as androgen receptor modulator compounds - Google Patents

Thiazole derivatives as androgen receptor modulator compounds Download PDF

Info

Publication number
WO2008124000A3
WO2008124000A3 PCT/US2008/004287 US2008004287W WO2008124000A3 WO 2008124000 A3 WO2008124000 A3 WO 2008124000A3 US 2008004287 W US2008004287 W US 2008004287W WO 2008124000 A3 WO2008124000 A3 WO 2008124000A3
Authority
WO
WIPO (PCT)
Prior art keywords
androgen receptor
receptor modulator
thiazole derivatives
modulator compounds
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/004287
Other languages
French (fr)
Other versions
WO2008124000A2 (en
Inventor
Lin Zhi
E Adam Kallel
Bao Ngoc Nguyen
Mark E Adams
Yixing Shen
Thomas Lot Stevens Lau
Jyun-Hung Chen
John S Tyhonas
Robert J Ardecky
Todd A Miller
Jon C Loren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ligand Pharmaceuticals Inc
Original Assignee
Ligand Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ligand Pharmaceuticals Inc filed Critical Ligand Pharmaceuticals Inc
Publication of WO2008124000A2 publication Critical patent/WO2008124000A2/en
Publication of WO2008124000A3 publication Critical patent/WO2008124000A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Provided herein are compounds of formula (I), (II), (III) or (IV) that bind to androgen receptors and/or modulate activity of androgen receptors and/or modulate the amount of androgen receptors and/or reduce the number of androgen receptors in a cell and/or degrade androgen receptors in a cell; and to methods for making and using such compounds. Also provided are compositions containing such compounds and methods for making and using such compositions.
PCT/US2008/004287 2007-04-02 2008-04-01 Thiazole derivatives as androgen receptor modulator compounds Ceased WO2008124000A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92165207P 2007-04-02 2007-04-02
US60/921,652 2007-04-02

Publications (2)

Publication Number Publication Date
WO2008124000A2 WO2008124000A2 (en) 2008-10-16
WO2008124000A3 true WO2008124000A3 (en) 2009-04-02

Family

ID=39737137

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/004287 Ceased WO2008124000A2 (en) 2007-04-02 2008-04-01 Thiazole derivatives as androgen receptor modulator compounds

Country Status (1)

Country Link
WO (1) WO2008124000A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9862714B2 (en) 2009-03-02 2018-01-09 Stemsynergy Therapeutics, Inc. Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR044519A1 (en) 2003-05-02 2005-09-14 Novartis Ag DERIVATIVES OF PIRIDIN-TIAZOL AMINA AND PIRIMIDIN-TIAZOL AMINA
PE20091523A1 (en) 2007-12-20 2009-10-29 Novartis Ag THIAZOL DERIVATIVES AS INHIBITORS OF THE ENZYME PHOSPHATIDYLINOSITOL 3-KINASE (PI3K)
MX2010009162A (en) 2008-02-22 2010-12-21 Radius Health Inc Selective androgen receptor modulators.
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
UA104147C2 (en) 2008-09-10 2014-01-10 Новартис Аг PYROLIDINDICARBONIC ACID DERIVATIVE AND ITS APPLICATION IN THE TREATMENT OF PROLIFERATIVE DISEASES
GB0905525D0 (en) * 2009-03-31 2009-05-13 Univ Leiden Compounds and uses
ES2432671T3 (en) 2009-07-02 2013-12-04 Novartis Ag 2-carboxamide cycloamine ureas useful as PI3K inhibitors
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
AR078793A1 (en) * 2009-10-27 2011-12-07 Orion Corp DERIVATIVES OF NON-STEROID CARBOXAMIDS AND ACIL HYDRAZONE MODULATORS OF ANDROGENIC RECEPTORS OF SELECTIVE FABRIC (SARM), PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE OF THE SAME IN THE TREATMENT OF PROSTATE CANCER BETWEEN OTHERS
EP2531029B1 (en) 2010-02-04 2016-10-19 Radius Health, Inc. Selective androgen receptor modulators
WO2011115998A2 (en) * 2010-03-17 2011-09-22 Taivex Therapeutics Inc. Modulators of hec1 activity and methods therefor
US20130053448A1 (en) 2010-05-12 2013-02-28 Louis O'Dea Therapeutic Regimens
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
CA2806766C (en) * 2010-07-28 2017-01-10 Neugen Pharma Inc. Novel amino imidazole compounds selectively suppress oxidative stress induced neurodegeneration
US9133182B2 (en) 2010-09-28 2015-09-15 Radius Health, Inc. Selective androgen receptor modulators
KR101958177B1 (en) * 2011-04-21 2019-03-15 오리온 코포레이션 Androgen receptor modulating carboxamides
US11071736B2 (en) 2011-11-21 2021-07-27 Taivex Therapeutics Corporation Modulators of HEC1 activity and methods therefor
WO2014063168A1 (en) 2012-10-19 2014-04-24 The Broad Institute, Inc. Heterocycle-bisamide inhibitors of scavenger receptor bl
WO2014063167A1 (en) * 2012-10-19 2014-04-24 The Broad Institute, Inc. Thiazole-based inhibitors of scavenger receptor bi
US20160046616A1 (en) * 2013-03-15 2016-02-18 The Johns Hopkins University Nrf2 small molecule inhibitors for cancer therapy
AU2014275643B2 (en) * 2013-06-05 2018-08-09 C&C Research Laboratories Heterocyclic derivatives and use thereof
EP3016950B1 (en) 2013-07-02 2017-06-07 Bristol-Myers Squibb Company Tricyclic pyrido-carboxamide derivatives as rock inhibitors
CN105492444B (en) 2013-07-02 2018-09-07 百时美施贵宝公司 Tricyclic pyridine-carboxamide derivatives as ROCK inhibitors
US20150126507A1 (en) * 2013-09-05 2015-05-07 Fate Therapeutics, Inc. Compounds to treat hearing loss
US9682960B2 (en) 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
WO2015129853A1 (en) * 2014-02-27 2015-09-03 東レ株式会社 Cyclic amine derivative and pharmaceutical use thereof
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
CA2943611A1 (en) 2014-03-28 2015-10-01 Duke University Method of treating cancer using selective estrogen receptor modulators
KR20160066490A (en) * 2014-12-02 2016-06-10 주식회사 씨앤드씨신약연구소 Heterocyclic derivatives and use thereof
WO2016089062A2 (en) 2014-12-02 2016-06-09 C&C Research Laboratories Heterocyclic derivatives and use thereof
ES2578363B1 (en) * 2015-01-22 2017-01-31 Palobiofarma, S.L. A3 adenosine receptor modulators
US10654809B2 (en) 2016-06-10 2020-05-19 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10017471B2 (en) 2015-04-21 2018-07-10 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US9834507B2 (en) 2015-04-21 2017-12-05 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10035763B2 (en) 2015-04-21 2018-07-31 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
AU2016250562B2 (en) * 2015-04-21 2020-08-13 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10865184B2 (en) 2015-04-21 2020-12-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
EP3286164B1 (en) 2015-04-21 2024-05-29 Oncternal Therapeutics, Inc. Selective androgen receptor degrader (sard) ligands and methods of use thereof
US10806720B2 (en) 2015-04-21 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10093613B2 (en) 2015-04-21 2018-10-09 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10441570B2 (en) 2015-04-21 2019-10-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) Ligands and methods of use thereof
CN113750091B (en) 2015-04-29 2025-03-11 雷迪厄斯制药公司 Methods for treating cancer
US11028061B2 (en) * 2015-07-27 2021-06-08 Sanford Burnham Prebys Medical Discovery Institute Modulators of myocyte lipid accumulation and insulin resistance and methods of use thereof
US11230523B2 (en) 2016-06-10 2022-01-25 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
MX389702B (en) 2016-06-22 2025-03-20 Ellipses Pharma Ltd COMPOUNDS FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR-EXPRESSING BREAST CANCER (AR+).
KR101983788B1 (en) * 2016-12-01 2019-05-30 서울대학교산학협력단 Amide derivative compounds, stereoisomer thereof, or pharmaceutically acceptable salts thereof, and pharmaceutical or cosmetic composition for antiaging, antiwrinkle, or wound healing on skin containing the same
US10385008B2 (en) 2017-01-05 2019-08-20 Radius Pharmaceuticals, Inc. Polymorphic forms of RAD1901-2HCL
KR102792490B1 (en) 2018-07-04 2025-04-04 래디어스 파마슈티컬스, 인코포레이티드 Polymorphic forms of RAD1901-2HCL
WO2020051344A1 (en) 2018-09-05 2020-03-12 University Of Tennessee Research Foundation Selective androgen receptor degrader (sard) ligands and methods of use thereof
US20230257357A1 (en) * 2020-06-29 2023-08-17 Bacainn Biotherapeutics, Ltd. Probenecid compounds for the treatment of inflammasome-mediated lung disease
WO2025120552A1 (en) * 2023-12-07 2025-06-12 제이더블유중외제약 주식회사 Solid dispersion including heterocycle derivative, method for preparing same, and pharmaceutical composition including same
WO2025120551A1 (en) * 2023-12-08 2025-06-12 제이더블유중외제약 주식회사 Intermediate compound used in preparing heterocycle derivative, method for preparing same, and method for preparing heterocycle derivative using same
WO2025120550A1 (en) * 2023-12-08 2025-06-12 제이더블유중외제약 주식회사 Intermediate compound used in preparing heterocycle derivative, method for preparing intermediate compound, and method for preparing heterocycle derivative using same

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1361220A1 (en) * 2001-01-26 2003-11-12 Shionogi & Co., Ltd. Cyclic compounds having thrombopoietin receptor agonism
WO2004041813A1 (en) * 2002-10-30 2004-05-21 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
WO2004096798A2 (en) * 2003-04-25 2004-11-11 Sanofi-Aventis Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and use of same as chemokine antagonists
WO2005025572A1 (en) * 2003-09-10 2005-03-24 Merck & Co., Inc. 17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators
WO2006116301A1 (en) * 2005-04-22 2006-11-02 The Johns Hopkins University Neuroprotective compounds for treating optic neuropathies

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1361220A1 (en) * 2001-01-26 2003-11-12 Shionogi & Co., Ltd. Cyclic compounds having thrombopoietin receptor agonism
WO2004041813A1 (en) * 2002-10-30 2004-05-21 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
WO2004096798A2 (en) * 2003-04-25 2004-11-11 Sanofi-Aventis Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and use of same as chemokine antagonists
WO2005025572A1 (en) * 2003-09-10 2005-03-24 Merck & Co., Inc. 17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators
WO2006116301A1 (en) * 2005-04-22 2006-11-02 The Johns Hopkins University Neuroprotective compounds for treating optic neuropathies

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9862714B2 (en) 2009-03-02 2018-01-09 Stemsynergy Therapeutics, Inc. Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell

Also Published As

Publication number Publication date
WO2008124000A2 (en) 2008-10-16

Similar Documents

Publication Publication Date Title
WO2008124000A3 (en) Thiazole derivatives as androgen receptor modulator compounds
WO2007005887A3 (en) Androgen receptor modulator compounds, compositions and uses thereof
WO2009082437A3 (en) Selective androgen receptor modulators (sarms) and uses thereof
EP2266056A4 (en) Dynamic formulas for spreadsheet cells
WO2009020234A3 (en) Pyrrolidin-2 -one derivatives as androgen receptor modulator
ZA201000127B (en) Novel 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors
GEP20125426B (en) Tricyclic compounds and their use as glucocorticoid receptor modulators
IL186700A0 (en) Immunoliposome composition for targeting to a her2 cell receptor
WO2008130953A3 (en) 2-imin0is0thiaz0le derivatives as cannabinoid receptor ligands
NO20074002L (en) Androgen receptor modulator compounds and methods
GB0901493D0 (en) Hydraulic cements comprising carbonate compounds compositions
WO2008064353A3 (en) 7,8-saturated-4,5-epoxy-morphinanium analogs
ZA201108618B (en) Stable topical compositions for 1,2,4-thiadiazole derivatives
EP2201078A4 (en) Improved sealing composition
IN2012DN02876A (en)
WO2011149993A3 (en) SUBSTITUTED OCTAHYDROCYCLOPENTA[c]PYRROLES AS CALCIUM CHANNEL MODULATORS
WO2010057088A3 (en) Pyrrolidinyl modulators of nicotinic acetylcholine receptors
IL189883A0 (en) Isoquinolines as igf-1r inhibitors
WO2011084434A3 (en) Aza-ring fused indole and indoline derivatives
WO2007075884A3 (en) Androgen receptor modulator compounds and methods
WO2009089479A3 (en) Inhibiting neurotransmitter reuptake
WO2006127871A3 (en) Cycloalkylidene compounds as selective estrogen receptor modulators
WO2008090231A3 (en) Method for preventing unwanted formation of hydrogen sulfide during the isolation of biogas by the addition of nitrate salts
WO2008030771A8 (en) Cyclic alkylidene compounds as selective estrogen receptor modulators
WO2009058951A3 (en) Process for the production of powder coating compositions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08727253

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08727253

Country of ref document: EP

Kind code of ref document: A2